According to a new report, the global diabetic population is set to
double by 2030, with treatments currently falling way short of
medical needs. The focus falls on impending products offering novel
therapies to diabetics and for...
The limited efficacy of existing diabetes therapies is set to pose
the main challenge for the European diabetes diagnostics markets as
the uptake and adoption for new innovative techniques determining
the future of this burgeoning...
Biovitrum and Santhera have announced the signing of an exclusive
license and collaboration agreement, which aims to develop DPP-IV
inhibitors for the treatment of type 2 diabetes and other metabolic
The latest research included in the proceedings of the annual
scientific meeting of the American Diabetes Association (ADA) means
that diabetic treatments and other therapies for the disease
feature strongly in DrugResearcher's...
Sangamo BioSciences has initiated a Phase I clinical trial for its
novel therapy for diabetic neuropathy that is designed to protect
and stimulate the regeneration of peripheral nerve function in
diabetics suffering from peripheral...
Innodia are to initiate a phase I trial of its lead drug candidate
for the treatment of type 2 diabetes with a view to bringing this
novel drug to market and the 170 million people affected by the
disease, a number that is expected...
Drug therapies for sufferers of diabetes may become a thing of the
past as UK doctors performed a groundbreaking cell transplant
technique on a patient making him the first person to be "cured" of
US scientists have demonstrated that by knocking out two key
signals in liver cells causes diabetes. These findings pave the way
for drug strategies to boost these two different signals and treat
the different metabolic components...
The lead agent in a new class of drugs for the treatment of
diabetes - Novartis' LAF-237 - seems to improve glucose control
without the weight gain associated with other orally-active drugs
for this common disease, reports Phil...